John L. Marshall, MD, The Ruesch Center for the Cure of GI Cancers

A panel of GI oncologists share their thoughts on the future of using precision medicine to treat patients with bile duct cancers.

The role of MSI testing and potential use of immunotherapy to treat patients with advanced cholangiocarcinoma.

An overview of various treatment opportunities under study that are looking at using novel techniques to help personalize treatment for patients with bile duct cancers.

Considerations for treating appropriate patients with advanced cholangiocarcinoma with an IDH inhibitor.

Milind Javle, MD, of The University of Texas MD Anderson Cancer Center, explains what GI oncologists can expect from FGFR treatment for advanced cholangiocarcinoma in terms of treatment responses.

Recommendations for appropriately managing patients who experience adverse events associated with FGFR treatment for advanced cholangiocarcinoma.

R. Kate Kelley, MD, of the UCSF Helen Diller Family Comprehensive Cancer Center, comments on the rationale for treating patients with advanced cholangiocarcinoma with an FGFR inhibitor.

The value of early molecular testing in cholangiocarcinoma and importance of promoting its role to both patients and GI oncologists.

Experts in CRC discuss questions and management of mCRC.

John Marshall, MD, and Axel Grothey, MD, discuss how molecular testing results guide treatment decisions in patients with mCRC.

Experts in mCRC review data on TAS-102 and discuss how best to sequence therapies in the third or fourth line.

Axel Grothey, MD, and John Marshall, MD, discuss safety results from the ReDOS study of regorafenib in patients with mCRC.

John Marshall, MD, reviews efficacy data from the ReDOS study of regorafenib in patients with mCRC.

Experts in metastatic colorectal cancer review therapeutic options after progression for patients with mCRC.

Experts in metastatic colorectal cancer discuss when and in which patients to use a chemotherapy-free treatment interval.

Axel Grothey, MD, and John Marshall, MD, discuss strategies for optimizing first-line treatment in metastatic colorectal cancer and the role of adjuvant therapy.

Axel Grothey, MD, and John Marshall, MD, discuss first-line treatment options in patients with metastatic colorectal cancer.

Axel Grothey, MD, discusses factors that influence treatment selection in patients with mCRC.